ArticleIndian journal of surgical oncology2026
Clinical Implications of Cytology Negative Pleural Effusion in Advanced Stage Epithelial Ovarian Cancer-Insights from a Tertiary Cancer Center in Northeast India.
Article in Indian journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pleural effusion is a decisive factor in advanced-stage ovarian cancer. The presence of malignant cells in pleural effusions in women with ovarian cancer is accepted as a poor prognostic factor. It is included in the International Federation of Gynecology and Obstetrics (FIGO) stage IVA. Still, the literature does not explain and prognoses the importance of cytology-negative pleural effusion (CNPE) in women with ovarian cancer. It is a retrospective study conducted in a tertiary cancer center. All advanced staged ovarian cancer patients with pleural effusion registered between January 2020 and December 2021 were included, and the control group consisted of all stage IIIC disease with no pleural effusion during the same duration. Survival analysis was done in these three groups-cytology-positive pleural effusion (CPPE), cytology-negative pleural effusion (CNPE), and no pleural effusion (NPE). In total, 117 patients with advanced-stage ovarian cancer, fulfilling the eligibility criteria, completed their treatment during the study period. Retrospective data was collected from hospital records, and survival analysis was done using SPSS 29.0. We included only those patients who had pleural fluid analyzed by a pathologist. During the study period, we found that 13 (11%) were CPPE, 23 (19.3%) were CNPE, and 81 (68%) were NPE. CNPE patients had poor progression-free survival (PFS) and overall survival (OS) compared to NPE patients, although both groups were labeled stage IIIC. These findings underscore the importance of cytology-negative pleural effusion in ovarian cancer prognosis, providing valuable insights for clinical practice. Patients with cytology-positive pleural effusion had the worst prognoses. However, CNPE patients labeled as stage IIIC had poor outcomes compared to NPE stage IIIC patients. So, based on our comprehensive study, we recommend a video thoracoscopic analysis of all patients with CNPE to correctly stage these patients, further modify their treatment accordingly, and improve their outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.